Literature DB >> 21381869

Hodgkin disease and the role of the immune system.

Alana A Kennedy-Nasser1, Patrick Hanley, Catherine M Bollard.   

Abstract

Hodgkin disease (HD) is a malignancy of primarily B lymphocytes that has the unique ability to cause immunodeficiency, as well as provide immune evasion mechanisms to avoid self-destruction. In this review, the authors discuss Hodgkin disease, its association with Epstein-Barr virus (EBV), the immune deficiency caused by HD, and tumor immune evasion mechanisms. Specifically, the authors closely evaluate the roles of regulatory T cells in HD, cytotoxic T cells, cytokine and chemokine secretion, down-regulation of Fas ligand, and indoleamine 2,3-dioxygenase (IDO) secretion.

Entities:  

Mesh:

Year:  2011        PMID: 21381869      PMCID: PMC3168532          DOI: 10.3109/08880018.2011.557261

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  95 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  T cells and tumours.

Authors:  D Pardoll
Journal:  Nature       Date:  2001-06-28       Impact factor: 49.962

Review 3.  Regulatory T cells in autoimmmunity*.

Authors:  E M Shevach
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  The role of chemokines in Hodgkin's disease.

Authors:  J Teruya-Feldstein; G Tosato; E S Jaffe
Journal:  Leuk Lymphoma       Date:  2000-07

Review 5.  Interleukin 13: a growth factor in hodgkin lymphoma.

Authors:  B F Skinnider; U Kapp; T W Mak
Journal:  Int Arch Allergy Immunol       Date:  2001-12       Impact factor: 2.749

6.  Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  B F Skinnider; A J Elia; R D Gascoyne; L H Trümper; F von Bonin; U Kapp; B Patterson; B E Snow; T W Mak
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

7.  HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease.

Authors:  Lea C Harty; Albert Y Lin; Alisa M Goldstein; Elaine S Jaffe; Mary Carrington; Margaret A Tucker; William S Modi
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

8.  Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells.

Authors:  Koichi Ohshima; Takeshi Tutiya; Takahiro Yamaguchi; Keiko Suzuki; Junji Suzumiya; Chika Kawasaki; Seiji Haraoka; Masahiro Kikuchi
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

Review 9.  Lymphocyte traffic control by chemokines.

Authors:  B Moser; P Loetscher
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

Review 10.  Epstein-Barr virus and Hodgkin's disease.

Authors:  L M Weiss
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

View more
  10 in total

1.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

2.  An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.

Authors:  Tobias Jahn; Martin Zuther; Björn Friedrichs; Claudia Heuser; Stefan Guhlke; Hinrich Abken; Andreas A Hombach
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

3.  Targeting two co-operating cytokines efficiently shapes immune responses.

Authors:  Andreas A Hombach; Hinrich Abken
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

4.  FAS system deregulation in T-cell lymphoblastic lymphoma.

Authors:  M Villa-Morales; M A Cobos; E González-Gugel; V Álvarez-Iglesias; B Martínez; M A Piris; A Carracedo; J Benítez; J Fernández-Piqueras
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

5.  A difficult diagnosis of Hodgkin lymphoma due to immune thrombocytopenia.

Authors:  Silvia Marino; Andrea Di Cataldo; Gaetano Magro; Salvatore D'Amico; Milena La Spina; Vincenzo Di Benedetto; Mariaclaudia Meli; Carla Moscheo; Giovanna Russo
Journal:  Clin Case Rep       Date:  2015-02-04

6.  Screening Strategies for COVID-19 in Patients With Hematologic Malignancies.

Authors:  Tarek Assi; Bachar Samra; Laurent Dercle; Elie Rassy; Joseph Kattan; Marwan Ghosn; Roch Houot; Samy Ammari
Journal:  Front Oncol       Date:  2020-07-03       Impact factor: 6.244

7.  Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence.

Authors:  Deniz Bakkalci; Yumeng Jia; Joanne R Winter; Joanna Ea Lewis; Graham S Taylor; Helen R Stagg
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

8.  Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study.

Authors:  Ji-Young Choe; Ji Yun Yun; Yoon Kyoung Jeon; Se Hoon Kim; Gyeongsin Park; Joo Ryoung Huh; Sohee Oh; Ji Eun Kim
Journal:  BMC Cancer       Date:  2014-05-15       Impact factor: 4.430

9.  Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells.

Authors:  Antonia Pavlovic; Merica Glavina Durdov; Vesna Capkun; Jasminka Jakelic Pitesa; Maja Bozic Sakic
Journal:  Med Sci Monit       Date:  2016-07-05

10.  Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma.

Authors:  Ombretta Repetto; Valli De Re; Lara Mussolin; Massimo Tedeschi; Caterina Elia; Maurizio Bianchi; Salvatore Buffardi; Alessandra Sala; Roberta Burnelli; Maurizio Mascarin
Journal:  Int J Mol Sci       Date:  2020-03-22       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.